Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Chi-Med to Announce 2020 Final Results
Hutchison China MediTech LimitedFebruary 3, 2021 GMT
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Feb. 03, 2021 (GLOBE NEWSWIRE) Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) will be announcing its final results for the year ended December 31, 2020 on Thursday, March 4, 2021 at 12:00 noon Greenwich Mean Time (GMT) / 8:00 pm Hong Kong Time (HKT) / 7:00 am Eastern Standard Time (EST).
Analysts and investors are invited to join a conference call and audio webcast presentation with Q&A, conducted by Chi-Med management.
The conference call and audio webcast will take place at 1:00 pm GMT / 9:00 pm HKT / 8:00 am EST on Thursday, March 4, 2021 and will be webcast live via the company website at www.chi-med.com/investors/event-information/. The presentation will be available for downloading before the conference call begin
TMCnet News
Chi-Med Initiates Rolling Submission of NDA to U.S. FDA for Surufatinib for the Treatment of Advanced Neuroendocrine Tumors
[December 28, 2020]
Chi-Med Initiates Rolling Submission of NDA to U.S. FDA for Surufatinib for the Treatment of Advanced Neuroendocrine Tumors
â Company plans to complete rolling submission in the first half of 2021 â
â The pivotal Phase III SANET-ep trial demonstrated surufatinib reduced risk of progression or death by 67%, extending PFS of
non-pancreatic NET patients with an acceptable risk/benefit ratio â
â The pivotal Phase III SANET-p trial demonstrated surufatinib reduced risk of progression or death by 51%, extending PFS of
pancreatic NET patients with an acceptable risk/benefit ratio â
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Chi-Med Initiates Rolling Submission of NDA to U.S. FDA for Surufatinib for the Treatment of .
Hutchison China MediTech LimitedDecember 28, 2020 GMT
– Company plans to complete rolling submission in the first half of 2021 –
– The pivotal Phase III SANET-ep trial demonstrated surufatinib reduced risk of progression or death by 67%, extending PFS of non-pancreatic NET patients with an acceptable risk/benefit ratio –
– The pivotal Phase III SANET-p trial demonstrated surufatinib reduced risk of progression or death by 51%, extending PFS of pancreatic NET patients with an acceptable risk/benefit ratio –
Chi-Med to Present at the 39th Annual JP Morgan Healthcare Conference – IT Business Net itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.
A
Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient: 1. Obtains access to the information in a personal capacity; 2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services; 3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body; 4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;